Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleomycin for Malignant Pericardial Effusion in Lung Cancer
NCT00132613Phase 3Completed
- Sponsor
- Japan Clinical Oncology Group
- Start
- Aug 1999
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in malignant pericardial effusion (MPE) comparing Observation alone with Bleomycin instillation (2 arms). Primary endpoint: Survival without pericardial effusion at 2 months. Started Aug 1999; status: completed.
02
Drugs
bleomycin
03
Conditions
malignant pericardial effusion (MPE)
Beyond the preview
Go deeper on NCT00132613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132613.